SCHEMBL808377

SCHEMBL808377

CCCC1CCC(NS(=O)(=O)c2ccc3ccccc3c2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.56
ALDH1A1 P00352 3/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
HDAC3 O15379 2/20 0.50
HDAC4 P56524 2/20 0.50
HDAC1 Q13547 2/20 0.50
HDAC7 Q8WUI4 2/20 0.50
HDAC2 Q92769 2/20 0.50
HDAC10 Q969S8 2/20 0.50
HDAC11 Q96DB2 2/20 0.50
HDAC8 Q9BY41 2/20 0.50
HDAC6 Q9UBN7 2/20 0.50
HDAC9 Q9UKV0 2/20 0.50
HDAC5 Q9UQL6 2/20 0.50
PARG Q86W56 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
ACACB O00763 1/20 0.48
NPY5R Q15761 2/20 0.48
DPP4 P27487 1/20 0.46
DPP7 Q9UHL4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16187960 0.87 KMT2A (0.56) KMT2AALDH1A1SMN1; SMN2HDAC3HDAC4
SCHEMBL3683615 0.86 KMT2A (0.69) KMT2AALDH1A1SMN1; SMN2PARGL3MBTL1
SCHEMBL23052423 0.81 KMT2A (0.66) KMT2AALDH1A1SMN1; SMN2PARGL3MBTL1
SCHEMBL2674938 0.79 KMT2A (0.64) KMT2AALDH1A1SMN1; SMN2PARGL3MBTL1
SCHEMBL8898830 0.78 ACACB (0.81) KMT2AALDH1A1SMN1; SMN2HDAC3HDAC4
SCHEMBL8898825 0.78 ACACB (0.81) KMT2AALDH1A1SMN1; SMN2HDAC3HDAC4
SCHEMBL516615 0.77 KMT2A (0.58) KMT2AALDH1A1SMN1; SMN2HDAC3HDAC4
SCHEMBL11830451 0.77 KMT2A (0.48) KMT2AALDH1A1SMN1; SMN2PARGLMNA
SCHEMBL933358 0.77 KMT2A (0.61) KMT2AALDH1A1SMN1; SMN2PARGL3MBTL1
SCHEMBL1048597 0.77 KMT2A (0.61) KMT2AALDH1A1SMN1; SMN2PARGL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9371286-B2 Pharmaceutical composition with enhanced efficacy for inhibiting angiogenesis INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) 2016-06-21 US disclosed
US-20140315947-A1 PHARMACEUTICAL COMPOSITION WITH ENHANCED EFFICACY FOR INHIBITING ANGIOGENESIS INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) 2014-10-23 US disclosed
WO-2012036512-A2 USE OF A COMPOUND FOR INDUCING DIFFERENTIATION OF MESENCHYMAL STEM CELLS INTO CARTILAGE CELLS 연세대학교 산학협력단 (KR) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315947-A1 PHARMACEUTICAL COMPOSITION WITH ENHANCED EFFICACY FOR INHIBITING ANGIOGENESIS UQCRB, UQCRC1, UQCRC2 KMT2A 4308/4885ALDH1A1 2079/4885SMN1; SMN2 2400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.